SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee joined Irth Capitals take-private bid have renewed buyout speculation. Traders are debating whether the board will accept a deal, against the backdrop of weak sales and previous rejected offers; no transaction is confirmed.

TOSHI

Renewed volume and choppy price action have traders watching for a breakout in TOSHI, with bullish posts anticipating a rally or short squeeze while skeptics point to repeated resistance and the risk of further lows. The discussion is largely speculative technical trading and community conviction around the Base meme coin, with no confirmed new catalyst dominating.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

New ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 breast cancer study are drawing attention, with traders highlighting promising efficacy while noting the topline results were already known. The community is split on whether the update adds a fresh catalyst, with discussion also focused on the FDA review of the PIK3CA-mutant label expansion and the need to demonstrate commercial sales.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks partnered personalized mRNA melanoma vaccine with Moderna is drawing attention after Phase 3 results showed reduced recurrence or death risk when added to Keytruda. Traders are split between viewing the data as a meaningful oncology milestone with potential to support Keytruda and seeing it as a sell-the-news outcome that fell short of high expectations.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is drawing attention amid a broad cybersecurity rally, as traders point to firmer enterprise security budgets and escalating AI-related vulnerabilities and cyber threats as demand tailwinds. The move has prompted bullish momentum talk, alongside concerns that high valuations leave the stock vulnerable to a pullback.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is drawing attention after a sharp third-quarter outlook cut tied to weak demand, excess distributor inventory, and price adjustments. Traders are split between viewing the reset and debt-reduction efforts as a path to recovery and fearing that persistent pressure on sales, margins, and debt could lead to restructuring or bankruptcy.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, largely sideways trading, with repeated technical posts describing consolidation and traders watching for a breakout. Optimistic holders are accumulating and anticipating a rebound, while skeptics point to the tokens lack of momentum and utility and expect further weakness.

Anthropic

Anthropics planned mega-IPO and reported financial disclosures are driving attention, with traders weighing rapid Claude revenue growth against heavy infrastructure commitments, losses, and an ambitious potential valuation. Bulls point to enterprise demand and pre-IPO exposure, while skeptics question the spending, competition, and sustainability of the business model.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvuss Phase 1 soquelitinib results in atopic dermatitis are driving discussion, with bullish traders highlighting the efficacy signal and skeptics questioning the early, limited data and follow-up. The news has prompted a mixed reaction, including complaints that shares sold off despite the positive readout.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer data for IMDELLTRA combined with AstraZenecas IMFINZI is drawing attention after showing a substantial survival benefit in extensive-stage small-cell lung cancer. Traders view the results as a potential growth driver for Amgens oncology pipeline, while also weighing established products such as Repatha and treating the companys AI story as a longer-term theme.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CL: filed in the Tom&#39;s of Maine settlement? Payments are expected around mid-November, about 60 days after final approval in the $2.9M case. Claims closed July 6, so filers just wait. Open Class Actions.

StockTwits Web

Colgate-Palmolive Co.

: filed in the Tom's of Maine settlement? Payments are expected around mid-November, about 60 days after final approval in the $2.9M case. Claims closed July 6, so filers just wait. Open Class Actions.